% | $
Quotes you view appear here for quick access.

OXiGENE, Inc. Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • ghosttraderg ghosttraderg Apr 23, 2012 4:30 PM Flag

    Dear Shareholders of OXiGENE

    "We are pleased to collaborate with the Leukemia and Lymphoma Society which is funding a Phase 1 investigator-sponsored trial of OXi4503 in AML. We anticipate seeing some initial data from this trial in late 2012 and final data in the first half of 2013.

    We believe that these data, if they are positive, will provide additional evidence of the broad clinical utility of our VDA pipeline, and attract additional commercial interest from potential partners. That is our major reason to continue to invest at a low level in maintaining these promising programs, and establishing collaborations that offset our expenses and enable them to advance without significant direct cost to the company."

0.70310.0000(0.00%)Jun 17 4:00 PMEDT